Abstract
Identification of patients at early risk for CVD improves risk stratification and patient management. Triglyceride glucose index can be used as a marker of atherosclerotic cardiovascular disease.
This study was approved by IRB of the institute and conducted in the period of July 2020 to June 2022 in the Chemical Pathology laboratory of Indus Hospital. All patients whose cardiac intervention (PCI/LHC) performed were included. Fasting lipid profile was analyzed on Alinity C analyzer, and FBS was measured on glucometer.
TyG index was calculated, 54% have TyG index more than 9.04. Male predominance was observed, with 68.6% falling within the <9.04 range and 60.4% within the >9.04 range. Patients aged over 50, constituting 51 (59.3%) in the <9.04 TG index group and 60 (59.4%) in the >9.04 TG index group.
Patients with TyG index <9.04, majority FBS is in pre-diabetic range 45.3% while TyG index >9.04 group, majority FBS is in diabetic range with a p-value of <0.001.
Our study demonstrated that the TyG index was independently associated with atherosclerosis in our population and this marker can be used for the prediction of disease for healthy individuals.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://submit.medrxiv.org/submission/queue?queueName=submission_in_progress
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board (IRB) of the Indus Hospital Karachi.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email address: muhammad.nizamuddin{at}tih.org.pk
Data Availability
All data produced in the present study are available upon reasonable request to the authors
https://submit.medrxiv.org/submission/queue?queueName=submission_in_progress
